Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 643.38 Million CNY | -76.64% |
| 2022 | 2.75 Billion CNY | 24.11% |
| 2021 | 2.21 Billion CNY | 47.03% |
| 2020 | 1.5 Billion CNY | 275.24% |
| 2019 | 402.33 Million CNY | 72.44% |
| 2018 | 233.32 Million CNY | 23.77% |
| 2017 | 188.5 Million CNY | 10.86% |
| 2016 | 170.03 Million CNY | 29.37% |
| 2015 | 131.43 Million CNY | 320.5% |
| 2014 | 31.25 Million CNY | -40.4% |
| 2013 | 52.44 Million CNY | 18.97% |
| 2012 | 44.08 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 108.28 Million CNY | 681.03% |
| 2024 Q1 | -18.63 Million CNY | -127.67% |
| 2024 Q3 | 4.18 Million CNY | -96.13% |
| 2023 Q3 | 291.17 Million CNY | 115.32% |
| 2023 Q4 | 67.36 Million CNY | -76.86% |
| 2023 FY | 643.38 Million CNY | -76.64% |
| 2023 Q1 | 149.61 Million CNY | -50.86% |
| 2023 Q2 | 135.23 Million CNY | -9.61% |
| 2022 Q3 | 805.37 Million CNY | 1.59% |
| 2022 Q2 | 792.79 Million CNY | -6.75% |
| 2022 Q1 | 850.17 Million CNY | 55.31% |
| 2022 FY | 2.75 Billion CNY | 24.11% |
| 2022 Q4 | 304.44 Million CNY | -62.2% |
| 2021 Q2 | 521.14 Million CNY | -3.15% |
| 2021 FY | 2.21 Billion CNY | 47.03% |
| 2021 Q4 | 547.41 Million CNY | -10.7% |
| 2021 Q1 | 538.09 Million CNY | 18.32% |
| 2021 Q3 | 612.99 Million CNY | 17.62% |
| 2020 Q1 | 47.91 Million CNY | -42.48% |
| 2020 Q2 | 507.98 Million CNY | 960.28% |
| 2020 FY | 1.5 Billion CNY | 275.24% |
| 2020 Q4 | 454.77 Million CNY | -8.87% |
| 2020 Q3 | 499.03 Million CNY | -1.76% |
| 2019 Q1 | 42.34 Million CNY | -38.62% |
| 2019 FY | 402.33 Million CNY | 72.44% |
| 2019 Q4 | 83.28 Million CNY | -43.47% |
| 2019 Q3 | 147.32 Million CNY | 13.87% |
| 2019 Q2 | 129.37 Million CNY | 205.51% |
| 2018 Q4 | 68.99 Million CNY | 0.95% |
| 2018 FY | 233.32 Million CNY | 23.77% |
| 2018 Q3 | 68.34 Million CNY | -21.03% |
| 2018 Q2 | 86.54 Million CNY | 818.12% |
| 2018 Q1 | 9.42 Million CNY | -76.98% |
| 2017 Q1 | 7.07 Million CNY | -86.04% |
| 2017 Q3 | 63.46 Million CNY | -17.59% |
| 2017 Q4 | 40.94 Million CNY | -35.49% |
| 2017 Q2 | 77.01 Million CNY | 989.06% |
| 2017 FY | 188.5 Million CNY | 10.86% |
| 2016 Q4 | 50.66 Million CNY | -10.53% |
| 2016 Q3 | 56.62 Million CNY | 0.0% |
| 2016 FY | 170.03 Million CNY | 29.37% |
| 2015 Q4 | 25.07 Million CNY | 0.0% |
| 2015 FY | 131.43 Million CNY | 320.5% |
| 2014 FY | 31.25 Million CNY | -40.4% |
| 2013 FY | 52.44 Million CNY | 18.97% |
| 2012 FY | 44.08 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 273.29 Million CNY | -135.415% |
| Joinn Laboratories(China)Co.,Ltd. | 396.99 Million CNY | -62.064% |
| WuXi AppTec Co., Ltd. | 9.6 Billion CNY | 93.303% |
| Autobio Diagnostics Co., Ltd. | 1.21 Billion CNY | 47.153% |
| Thalys Medical Technology Group Inc. | -158.57 Million CNY | 505.736% |
| Chemclin Diagnostics Co., Ltd. | 147.37 Million CNY | -336.566% |